Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients with incomplete healing.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or intravenously twice daily. Doses may be adjusted upwards based on symptom control and gastric acid output. Doses up to 240 mg intravenously daily have been used.
## Pediatric Dosing
* **Erosive esophagitis (ages 5 to 16 years):** 20 mg or 40 mg orally once daily. The choice of dose depends on individual patient needs and response. Dosing for patients weighing < 40 kg should generally be 20 mg once daily. Dosing for patients weighing $\ge$ 40 kg can be 20 mg or 40 mg once daily.
* Dosing for children under 5 years of age is not established.
## Dose Adjustments
* **Hepatic impairment:** Maximum daily dose of 40 mg orally or intravenously.
* **Renal impairment:** No dose adjustment is generally needed.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Certain antiretrovirals:** Pantoprazole can decrease the absorption of antiretrovirals with pH-dependent absorption (e.g., rilpivirine, nelfinavir).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with drugs primarily metabolized by this enzyme where narrow therapeutic windows exist.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias).
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Consider monitoring vitamin B12 levels with prolonged therapy.
* For hypersecretory conditions, monitor gastric acid output.
## Clinical Pearls
* Administer pantoprazole delayed-release tablets 30 minutes before a meal.
* When administered intravenously, reconstitute and dilute per manufacturer's instructions. Infuse over 15 minutes.
* Long-term use (typically >1 year) should be periodically reassessed for continued need.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols.*
